These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16103457)

  • 1. Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta.
    Douglas JA; Zuhlke KA; Beebe-Dimmer J; Levin AM; Gruber SB; Wood DP; Cooney KA
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2035-9. PubMed ID: 16103457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
    Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
    Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
    dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
    DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
    Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
    Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
    Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
    Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.
    Azzouzi AR; Cochand-Priollet B; Mangin P; Fournier G; Berthon P; Latil A; Cussenot O
    Eur J Endocrinol; 2002 Oct; 147(4):479-84. PubMed ID: 12370109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer associated with CYP17 genotype.
    Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
    Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
    Berstein LM; Imyanitov EN; Kovalevskij AJ; Maximov SJ; Vasilyev DA; Buslov KG; Sokolenko AP; Iyevleva AG; Chekmariova EV; Thijssen JH
    Cancer Lett; 2004 Apr; 207(2):191-6. PubMed ID: 15072828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
    Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
    Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
    Tigli H; Yazici H; Dalay N
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    Cussenot O; Azzouzi AR; Nicolaiew N; Fromont G; Mangin P; Cormier L; Fournier G; Valeri A; Larre S; Thibault F; Giordanella JP; Pouchard M; Zheng Y; Hamdy FC; Cox A; Cancel-Tassin G
    J Clin Oncol; 2007 Aug; 25(24):3596-602. PubMed ID: 17704407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
    Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
    Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
    Chang B; Zheng SL; Isaacs SD; Wiley KE; Carpten JD; Hawkins GA; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
    Int J Cancer; 2001 Nov; 95(6):354-9. PubMed ID: 11668516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
    Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
    DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an iranian population.
    Karimpur-Zahmatkesh A; Farzaneh F; Pouresmaeili F; Hosseini J; Azarghashb E; Yaghoobi M
    Asian Pac J Cancer Prev; 2013; 14(2):1049-52. PubMed ID: 23621184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
    Iwasaki M; Hamada GS; Nishimoto IN; Netto MM; Motola J; Laginha FM; Kasuga Y; Yokoyama S; Onuma H; Nishimura H; Kusama R; Kobayashi M; Ishihara J; Yamamoto S; Hanaoka T; Tsugane S
    Nutr Cancer; 2010; 62(4):466-75. PubMed ID: 20432167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
    Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.